The Mvt-1/Brd4 microarray expression signature predicts survival and/or relapse in multiple breast cancer microarray datasets. (A) The Brd4 signature consistently and robustly predicts survival and/or relapse in four separate breast cancer microarray datasets performed on Affymetrix GeneChips. A significant difference in the overall likelihood of survival was observed in the GSE1456 dataset with 8-year survival being 95.9% vs. 65.5% for the good and poor prognosis Brd4 signatures, respectively (Upper Left). A similar effect was observed in the GSE3494 dataset with 12-year survival being 80.6% vs. 57.5% for the good and poor prognosis Brd4 signatures, respectively (Upper Right). The end point for the GSE2034 and GSE4922 differ in that disease-free survival was measured. A similar effect was seen in both cohorts with 10-year disease-free survival being 68.9% vs. 54.2% in the GSE2034 dataset (Lower Left) and 71.3% vs. 47.6% in the GSE4922 dataset (Lower Right) for the good and poor prognosis Brd4 signatures, respectively. (B) The Brd4 signature was also highly predictive of overall survival in the Dutch Rosetta dataset, with the overall survival being estimated to be 78.5% vs. 45.1% for the good and poor prognosis Brd4 signatures, respectively (Brd4 signature hazard ratio = 5.50, 95% C.I. = 3.12–9.69) (Left) compared with 72.6% vs. 47.0%, respectively (70 gene signature hazard ratio = 4.49, 95% C.I. = 2.65–7.61) for the same analysis, using the Rosetta 70 gene signature.